Disclaim of the Chagas disease case in Blood Center is based on the immunofluorescence and enzyme-linked immunosorbent antibody assays. Methods: The antibody assays were conducted in parallel with the nuclear DNA-PCR test in blood samples of 145 families' members. Result: The specific antibody tests were positive in 26.9% (39/145) subjects. Contrastingly, the Trypanosoma cruzi nuclear DNA-PCR was positive in 72.4% (105/145) of those blood samples. Conclusion: The immune tolerance herein

more »

... the reported discrepancies of results between the specific antibody and the accurate DNA analysis. The warranty of safe blood transfusion is achieved by the PCR technology. Conclusion Chagas disease requires skilled personnel at the clinical center, hospital, and blood bank in order to disclaim donation candidate with basis on epidemiologic history, clinic evaluation, and ELISA serology and nucleic acids test. In view of insurmountable demand, quick and accurate nucleic acids diagnosis is essential for disclaim blood donor candidate. The development of an automated digital platform for throughput nucleic acid diagnostics is essential for blood donor disclaimers. The up-date technology proposal of molecular diagnosis will bring in short term low-cost prevention of Chagas disease. Ethical statement Not applicable.